If I may, Mr. Chair, I would like to add to your point. What we've done, as part of our efforts to take a closer look at projects and understand the risks, is to, through consultations with experts in addiction medicine, understand what the top tier and the top thresholds of safeguards are that can be put in place when dealing with substitution therapy of any kind when a narcotic is involved. We would then apply those in the context of these projects.
To the earlier question, we will be prepared to move very quickly where we encounter evidence of systemic harm.
Yes, regarding Switzerland, we're very interested in the work being done in Switzerland with its heroin-assisted treatment program. They do seven-day carries now as part of an unsupervised dosing program, which we are studying very carefully to take as much from that experience as we can and apply it in Canada.